Page last updated: 2024-11-06

denaverine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Denaverine is a synthetic spasmolytic drug that acts primarily as a non-selective phosphodiesterase inhibitor. Its mechanism of action involves increasing intracellular cyclic adenosine monophosphate (cAMP) levels, leading to smooth muscle relaxation. Denaverine is used to treat various conditions related to smooth muscle spasms, including biliary colic, renal colic, and dysmenorrhea. Its clinical efficacy has been established in multiple studies, and its safety profile is generally considered favorable. Research on denaverine focuses on understanding its precise mechanism of action, exploring potential applications beyond its current indications, and optimizing its pharmacological properties. The compound has also been studied for its potential use in managing other conditions, such as irritable bowel syndrome and chronic obstructive pulmonary disease, but further investigation is required.'

denaverine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID71130
CHEMBL ID1614656
CHEBI ID135601
SCHEMBL ID147346
MeSH IDM0042387

Synonyms (21)

Synonym
denaverine
CHEBI:135601
D07787
3579-62-2
denaverine (inn)
denaverina
denaverinum
unii-o14nf38mtl
2-(dimethylamino)ethyl-o-(2-ethylbutyl)benzilate
denaverina [inn-spanish]
denaverinum [inn-latin]
denaverine [inn]
o14nf38mtl ,
2-(dimethylamino)ethyl (2-ethylbutoxy)diphenylacetate
CHEMBL1614656
denaverine [who-dd]
SCHEMBL147346
DTXSID10189315
denaverin
2-(dimethylamino)ethyl 2-(2-ethylbutoxy)-2,2-diphenylacetate
Q1186872

Research Excerpts

Overview

Denaverine hydrochloride is a regularly used substance in obstetrics in veterinary medicine in many European countries.

ExcerptReferenceRelevance
"Denaverine hydrochloride is a regularly used substance in obstetrics in veterinary medicine in many European countries. "( Effect of denaverine hydrochloride application to heifers on the APGAR score and lactate concentration in newborn calves.
Fischer-Tenhagen, C; Heuwieser, W; Lange, K, 2018
)
2.33

Pharmacokinetics

ExcerptReferenceRelevance
" Despite its commercial availability as a solution for intravenous or intramuscular administration (ampoule) and as a suppository formulation, no pharmacokinetic data in man was available to date."( Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral and rectal single doses.
Blume, H; Elze, M; Larsimont, V; Mutschler, E; Schug, BS; Staab, A; Thümmler, D, 2003
)
0.59
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35

Bioavailability

ExcerptReferenceRelevance
" Therefore, the objectives of this clinical trial were to determine the basic pharmacokinetic parameters of denaverine after intravenous administration, to assess the feasibility of using the oral route of administration and to characterise the bioavailability of the suppository formulation."( Pharmacokinetics and bioavailability of denaverine hydrochloride in healthy subjects following intravenous, oral and rectal single doses.
Blume, H; Elze, M; Larsimont, V; Mutschler, E; Schug, BS; Staab, A; Thümmler, D, 2003
)
0.8

Dosage Studied

ExcerptRelevanceReference
" The first dosage was 100 mg of all substances."( [Use of tramadol versus pethidine versus denaverine suppositories in labor--a contribution to noninvasive therapy of labor pain].
Bredow, V, 1992
)
0.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diarylmethaneAny compound containing two aryl groups connected by a single C atom.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (21.43)18.7374
1990's1 (7.14)18.2507
2000's5 (35.71)29.6817
2010's5 (35.71)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.37 (24.57)
Research Supply Index2.94 (2.92)
Research Growth Index4.67 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials4 (28.57%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (71.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]